These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23505468)

  • 1. Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations.
    Ramalho-Carvalho J; Pires M; Lisboa S; Graça I; Rocha P; Barros-Silva JD; Savva-Bordalo J; Maurício J; Resende M; Teixeira MR; Honavar M; Henrique R; Jerónimo C
    PLoS One; 2013; 8(3):e58206. PubMed ID: 23505468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
    Jeuken JW; Cornelissen SJ; Vriezen M; Dekkers MM; Errami A; Sijben A; Boots-Sprenger SH; Wesseling P
    Lab Invest; 2007 Oct; 87(10):1055-65. PubMed ID: 17700563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
    Bady P; Delorenzi M; Hegi ME
    J Mol Diagn; 2016 May; 18(3):350-361. PubMed ID: 26927331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis.
    Olson RA; Brastianos PK; Palma DA
    J Neurooncol; 2011 Nov; 105(2):325-35. PubMed ID: 21523485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    Ang SYL; Lee L; See AAQ; Ang TY; Ang BT; King NKK
    BMC Cancer; 2020 Jan; 20(1):79. PubMed ID: 32005184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
    Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
    J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.
    Gömöri E; Pál J; Kovács B; Dóczi T
    Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
    Håvik AB; Brandal P; Honne H; Dahlback HS; Scheie D; Hektoen M; Meling TR; Helseth E; Heim S; Lothe RA; Lind GE
    J Transl Med; 2012 Mar; 10():36. PubMed ID: 22390413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity.
    Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N
    Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
    Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
    J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.
    Trabelsi S; Mama N; Ladib M; Karmeni N; Haddaji Mastouri M; Chourabi M; Mokni M; Tlili K; Krifa H; Yacoubi MT; Saad A; H'mida Ben Brahim D
    Clin Transl Oncol; 2016 Apr; 18(4):391-7. PubMed ID: 26289551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
    Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
    Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
    Wang L; Li Z; Liu C; Chen L; Liu L; Hu Z; Zhao L; Lu D; Teng L
    Pathol Res Pract; 2017 Dec; 213(12):1489-1493. PubMed ID: 29103769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
    Ohka F; Natsume A; Motomura K; Kishida Y; Kondo Y; Abe T; Nakasu Y; Namba H; Wakai K; Fukui T; Momota H; Iwami K; Kinjo S; Ito M; Fujii M; Wakabayashi T
    PLoS One; 2011; 6(8):e23332. PubMed ID: 21829728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
    Ochsenbein AF; Schubert AD; Vassella E; Mariani L
    J Neurooncol; 2011 Jun; 103(2):343-51. PubMed ID: 20857319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.